ArticleDEN open2026
Epidemiology and Recurrence of Sigmoid Volvulus: Analysis of Health Insurance Claims Data in Japan.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Epidemiology and Recurrence of Sigmoid Volvulus: Analysis of Health Insurance Claims Data in Japan.DEN open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Sigmoid volvulus (SV) is rare in Japan, and most studies have been limited to small numbers or case series reports. We aimed to explore the incidence, risk factors, and recurrence rates of SV in Japan using community-based health insurance claims data. Methods: We used health insurance claims data from the Toyama Prefecture from April 2018 to March 2022. Individuals aged ≥ 40 years who had no diagnosis of SV (International Statistical Classification of Diseases, 10th Revision) in 2018 were included in our study. Patients who were newly diagnosed with SV in 2019 were identified. The annual incidence, risk factors, and recurrence rates of SV within 2 years of the first endoscopic reduction were evaluated. Poisson regression analysis was employed to identify risk factors, and Kaplan-Meier analysis was performed to analyze recurrence. Results: Of the 327,693 insured individuals in Toyama, 52 developed SV in 2019 (0.0159% = 15.9/100,000). Men (adjusted rate ratio [aRR] = 3.46, 95% confidence interval [CI]: 1.92- 6.25), constipation (aRR = 4.63, 95% CI: 2.50-8.58), and higher disability levels (level 2-3: aRR = 6.54, 95% CI: 2.43-13.57, level 4-5: RR = 2.94, 95% CI: 1.10-7.84) were significantly associated with SV incidence. Of the 45 patients who underwent only endoscopic reduction, recurrence within 2 years was observed in 16 (cumulative recurrence rate, 35.6%). Conclusions: SV is common in community-based studies. Men, constipation, and a high disability level were risk factors. The recurrence rate of SV after endoscopic reduction was approximately 35% within 2 years. Our insurance claims data offered valuable insights into SV epidemiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.